Travere Therapeutics (TVTX) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Travere Therapeutics (TVTX) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 99.9% versus a loss of 14.4%. Over five years, TVTX leads with a +112.8% price change compared with +9.3% for VRDN. Travere Therapeutics is the larger company by market cap ($4.91 billion vs $2.11 billion), about 2.3 times the size, while Viridian Therapeutics is growing revenue faster (+23359.9% vs +110.5%).
Travere Therapeutics converts more of its revenue into profit, with a net margin of -5.2% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TVTX | VRDN |
|---|---|---|
| Share price | $52.13 | $18.66 |
| Market cap | $4.91B | $2.11B |
| 1-day change | +0.16% | +1.74% |
| YTD return | +36.42% | -40.04% |
| 1-year return | +99.94% | -14.44% |
| 5-year return | +112.76% | +9.31% |
| Forward P/E | 9.24 | — |
| EPS (TTM) | $-0.75 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $490.73M | $70.85M |
| Revenue growth (YoY) | +110.45% | +23359.93% |
| Net income (latest FY) | $-25.55M | $-342.60M |
| Gross margin | 97.89% | — |
| Operating margin | -12.80% | -512.91% |
| Net margin | -5.21% | -483.57% |
| 52-week high | $68.73 | $34.29 |
| 52-week low | $22.59 | $13.18 |
| Distance from 52-week high | -24.16% | -45.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +44.29% | +96.95% |
| Average volume | 1.59M | 1.71M |
| Shares outstanding | 94.26M | 113.29M |
| Employees | 497 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Travere Therapeutics is about 2.3 times larger than Viridian Therapeutics by market value ($4.91B vs $2.11B).
- TVTX has outperformed VRDN by 114.4 percentage points over the past year.
- Travere Therapeutics is more profitable, keeping -5.2 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +110.45%).
About Travere Therapeutics
TVTX stock →Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Health Care · Biotechnology: Pharmaceutical Preparations · 497 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
TVTX vs VRDN FAQ
Which is bigger, Travere Therapeutics or Viridian Therapeutics?
Travere Therapeutics (TVTX) is larger, with a market capitalization of $4.91B compared with $2.11B for Viridian Therapeutics (VRDN).
Which stock has performed better over the past year, TVTX or VRDN?
TVTX returned +99.94% over the past 12 months, compared with -14.44% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are Travere Therapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.